SkinBioTherapeutics PLC (GB:SBTX)
LSE:SBTX
Holding GB:SBTX?
Track your performance easily

SkinBioTherapeutics (SBTX) Income Statement

7 Followers

SkinBioTherapeutics Income Statement

Last quarter (Q2 2023), SkinBioTherapeutics's total revenue was £―, a decrease of ― from the same quarter last year. In Q2, SkinBioTherapeutics's net income was £―. See SkinBioTherapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Jun 23Jun 22Jun 21Jun 20Jun 19
Total Revenue
-£ 132.06K£ 74.76K-£ 0.00£ 0.00
Cost of Revenue
-£ 46.87K£ 29.42K---
Gross Profit
-£ 85.19K£ 45.34K---
Operating Expense
-£ 3.05M£ 2.76M£ 1.49M£ 1.62M£ 1.36M
Operating Income
-£ -2.97M£ -2.71M£ -1.49M£ -1.62M£ -1.36M
Net Non Operating Interest Income Expense
-£ -8.89K£ -10.13K£ 926.00£ 0.00£ 0.00
Other Income Expense
-£ -3.29K£ 267.19K---
Pretax Income
-£ -3.01M£ -2.99M£ -1.50M£ -1.62M£ -1.36M
Tax Provision
-£ -173.09K£ -199.62K£ -65.06K£ -119.96K£ -212.39K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
-£ -2.84M£ -2.79M£ -1.43M£ -1.50M£ -1.15M
Basic EPS
-£ -0.02£ -0.02£ -0.01£ -0.01£ >-0.01
Diluted EPS
-£ -0.02£ -0.02£ -0.01£ -0.01£ >-0.01
Basic Average Shares
-£ 164.71M£ 156.78M£ 146.70M£ 128.08M£ 122.37M
Diluted Average Shares
-£ 164.71M£ 156.78M£ 146.70M£ 128.08M£ 122.37M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
-£ 3.10M£ 2.79M£ -1.49M£ 1.62M£ 1.36M
Net Income From Continuing And Discontinued Operation
-£ -2.84M£ -2.79M£ -1.43M£ -1.50M£ -1.15M
Normalized Income
-£ -3.15M£ -2.93M£ -1.56M£ -1.50M£ -1.15M
Interest Expense
----£ 0.00£ 0.00
EBIT
-£ -3.00M£ -2.98M£ -1.50M£ -1.62M£ -1.36M
EBITDA
-£ -2.95M£ -2.94M£ -1.50M£ -1.61M£ -1.36M
Currency in GBP

SkinBioTherapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis